PedAM

Pediatric Disease Annotations & Medicines


	oliguria

Disease ID	1662
Disease	oliguria
Definition	Decreased URINE output that is below the normal range. Oliguria can be defined as urine output of less than or equal to 0.5 or 1 ml/kg/hr depending on the age.
Synonym	[d]oliguria [d]oliguria (context-dependent category) [d]oliguria (situation) decrease urination decreased output urine decreased urine output decreased urine output (finding) decreased urine volume low urine output oligouria oliguria (finding) oliguria [disease/finding] oligurias passes too little urine urination decrease urine output decreased urine output low urine production scanty urine volume deficient volume urine decreased
UMLS	C0028961
MeSH	D009846
SNOMED-CT	SNOMEDCT_US_2016_09_01:83128009
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:14) C0035078 \| renal failure \| 13 C0022660 \| acute renal failure \| 9 C0033687 \| proteinuria \| 3 C1565489 \| renal insufficiency \| 2 C0032914 \| preeclampsia \| 1 C0023533 \| leukorrhea \| 1 C0034063 \| pulmonary edema \| 1 C0015230 \| rash \| 1 C0023364 \| leptospirosis \| 1 C0041948 \| uremia \| 1 C0035229 \| respiratory insufficiency \| 1 C0079924 \| oligohydramnios \| 1 C0022661 \| chronic renal failure \| 1 C0018801 \| heart failure \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:4) POMC \| 5443 \| CTD_human AVPR2 \| 554 \| CTD_human HBG2 \| 3048 \| CTD_human UOX \| 391051 \| CTD_human
Inferring Gene	(Waiting for update.)
Text Mined Gene	(Waiting for update.)
Locus	(Waiting for update.)

Disease ID	1662
Disease	oliguria
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:33) HP:0000083 \| Renal insufficiency \| 15 HP:0001919 \| Acute renal failure \| 10 HP:0012531 \| Pain \| 6 HP:0000093 \| Proteinuria \| 3 HP:0001944 \| Dehydration \| 2 HP:0002157 \| Azotaemia \| 2 HP:0001945 \| Fever \| 2 HP:0002098 \| Respiratory distress \| 2 HP:0100539 \| Periorbital swelling \| 1 HP:0001942 \| Metabolic acidosis \| 1 HP:0003256 \| Coagulopathy \| 1 HP:0002202 \| Pleural effusion \| 1 HP:0004756 \| Ventricular tachycardia \| 1 HP:0003201 \| Rhabdomyolysis \| 1 HP:0100806 \| Sepsis \| 1 HP:0000969 \| Dropsy \| 1 HP:0002615 \| Low blood pressure \| 1 HP:0000790 \| Hematuria \| 1 HP:0001279 \| Syncope \| 1 HP:0003418 \| Back pain \| 1 HP:0004755 \| Supraventricular tachycardia \| 1 HP:0100598 \| Pulmonary oedema \| 1 HP:0008711 \| Benign prostatic hypertrophy \| 1 HP:0011134 \| Mild fever \| 1 HP:0010783 \| Erythema \| 1 HP:0003774 \| End-stage renal failure \| 1 HP:0001635 \| Congestive heart failure \| 1 HP:0100602 \| Pre-eclampsia \| 1 HP:0001941 \| acidemia \| 1 HP:0002013 \| Emesis \| 1 HP:0002093 \| progressive respiratory failure \| 1 HP:0100749 \| Thoracic pain \| 1 HP:0001562 \| Oligohydramnios \| 1

Disease ID	1662
Disease	oliguria
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:3) C0030193 \| pain \| 6 C1565489 \| renal insufficiency \| 2 C0020649 \| hypotension \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:27)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0028961	acetaminophen	D000082	103-90-2	oliguria	MESH:D009846	marker/mechanism	2599669
C0028961	bendamustine hydrochloride	D000069461	-	oliguria	MESH:D009846	marker/mechanism	16313266
C0028961	colchicine	D003078	64-86-8	oliguria	MESH:D009846	marker/mechanism	16240705
C0028961	cyclophosphamide	D003520	50-18-0	oliguria	MESH:D009846	marker/mechanism	18398616
C0028961	diatrizoate	D003973	117-96-4	oliguria	MESH:D009846	marker/mechanism	4406739
C0028961	diclofenac	D004008	15307-86-5	oliguria	MESH:D009846	marker/mechanism	10773765
C0028961	diltiazem	D004110	42399-41-7	oliguria	MESH:D009846	marker/mechanism	3120959
C0028961	enalapril	D004656	75847-73-3	oliguria	MESH:D009846	marker/mechanism	16147831
C0028961	enflurane	D004737	13838-16-9	oliguria	MESH:D009846	marker/mechanism	973714
C0028961	esmolol	C036604	84057-94-3	oliguria	MESH:D009846	marker/mechanism	2900259
C0028961	ethambutol	D004977	74-55-5	oliguria	MESH:D009846	marker/mechanism	15102986
C0028961	indomethacin	D007213	53-86-1	oliguria	MESH:D009846	marker/mechanism	10974130
C0028961	lovastatin	D008148	75330-75-5	oliguria	MESH:D009846	marker/mechanism	8767987
C0028961	mesna	D015080	19767-45-4	oliguria	MESH:D009846	marker/mechanism	16333822
C0028961	methadone	D008691	76-99-3	oliguria	MESH:D009846	marker/mechanism	4936579
C0028961	mitomycin	D016685	1950/7/7	oliguria	MESH:D009846	marker/mechanism	6437662
C0028961	morphine	D009020	57-27-2	oliguria	MESH:D009846	marker/mechanism	12710656
C0028961	moxifloxacin	C104727	-	oliguria	MESH:D009846	marker/mechanism	20731847
C0028961	norepinephrine	D009638	51-41-2	oliguria	MESH:D009846	marker/mechanism	618599
C0028961	oxytetracycline	D010118	79-57-2	oliguria	MESH:D009846	marker/mechanism	7364640
C0028961	rifampin	D012293	13292-46-1	oliguria	MESH:D009846	marker/mechanism	76779
C0028961	tacrolimus	D016559	109581-93-3	oliguria	MESH:D009846	marker/mechanism	15840666
C0028961	tenofovir	D000068698	-	oliguria	MESH:D009846	marker/mechanism	12684925
C0028961	theophylline	D013806	58-55-9	oliguria	MESH:D009846	therapeutic	15840666
C0028961	ticlopidine	D013988	55142-85-3	oliguria	MESH:D009846	marker/mechanism	19309387
C0028961	tretinoin	D014212	302-79-4	oliguria	MESH:D009846	marker/mechanism	16858973
C0028961	vancomycin	D014640	1404-90-6	oliguria	MESH:D009846	marker/mechanism	3986655

FDA approved drug and dosage information(Total Drugs:7)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D009846	mevacor	lovastatin	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D009846	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D009846	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D009846	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D009846	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D009846	treanda	bendamustine hydrochloride	100MG/VIAL	POWDER;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D009846	treanda	bendamustine hydrochloride	100MG	INJECTABLE; INJECTION	Prescription	None	TBD	No

FDA labeling changes(Total Drugs:7)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D009846	02/14/2002	mevacor	lovastatin	Heterozygous Familial Hypercholesterolemia	New indication in adolescent boys and girls (at least one year post-menarche) 10-17 years of age	Labeling	B	-	-	-	Merck	07/17/2001	FALSE'
MESH:D009846	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D009846	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D009846	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D009846	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D009846	06/26/2012	treanda	bendamustine hydrochloride	Relapsed or refractory acute leukemia	Effectiveness in pediatric patients has not been established Treanda was evaluated in a Phase 1/2 trial in pediatric patients with leukemia The safety profile in pediatric patients was consistent with that seen in adults, and no new safety signals were identified Information on dosing, clinical trials and PK parameters	Labeling	B	-	-	-	-	-	FALSE'
MESH:D009846	06/26/2012	treanda	bendamustine hydrochloride	Relapsed or refractory acute leukemia	Effectiveness in pediatric patients has not been established Treanda was evaluated in a Phase 1/2 trial in pediatric patients with leukemia The safety profile in pediatric patients was consistent with that seen in adults, and no new safety signals were identified Information on dosing, clinical trials and PK parameters	Labeling	B	-	-	-	-	-	FALSE'